# Doctor



## Vaccines effective for prevention of rotavirus diarrhoea

### **Clinical question**

How effective are vaccines for preventing rotavirus diarrhoea?

#### **Bottom line**

Compared with placebo, Rotarix (given between 1 and 3 months of age) reduced cases of rotavirus diarrhoea by 83% in the first year and 52% in the second year. It also reduced hospitalisations by 81% after 1 year and 84% at 2 years. Compared with placebo, RotaTeq (given between 1 and 6 months of age) reduced cases of rotavirus diarrhoea by 73% after 1 year and 62% during the 2nd year. It also reduced hospitalisations by 96% after 1 year. The vaccines tested against placebo gave a similar number of adverse events such as deaths, reaction to the vaccine, and others that required discontinuation of the vaccination schedule.

## Caveat

All the included trials were placebo controlled, which means there are no data directly comparing Rotarix and RotaTeq. The trials provided only limited data for special groups of children, such as preterm infants and malnourished children.

#### Context

Rotavirus infections cause over half a million deaths per year in children younger than 5 years, especially in low-income and middle-income countries. Since 2009, the World Health Organization has recommended rotavirus vaccination be included in national immunisation programmes, especially in countries with a high burden of diarrhoeal deaths in children younger than 5 years.

## **Cochrane Systematic Review**

Soares-Weiser K et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Reviews, 2010, Issue 5. Article No. CD008521. DOI: 10.1002/14651858.CD008521. *This review contains 34 trials involving 175,944 participants.* 

PEARLS No. 279, July 2010, written by Brian R McAvoy

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners – developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the New Zealand Guidelines Group. New Zealanders can access the Cochrane Library free via www.nzgg.org.nz

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online at: www.nzdoctor.co.nz; www.nzgg.org.nz; www.cochraneprimarycare.org



